Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COYA Coya Therapeutics	$6.15 +8.1%	$5.96	$4.65 ▼ $10.24	$102.89M	0.26	73,872 shs	23,108 shs
JATT JATT Acquisition	$1.72 +8.2%	$1.35	$7.80 ▼ $12.38	$29.67M	N/A	41,322 shs	378,508 shs
MGNX MacroGenics	$1.58 -2.5%	$1.52	$0.99 ▼ $5.10	$99.68M	1.65	917,771 shs	530,539 shs
ZURA Zura Bio	$1.66 -3.5%	$1.36	$0.97 ▼ $5.07	$113.51M	-0.06	516,736 shs	470,799 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COYA Coya Therapeutics	-8.39%	-6.89%	-6.12%	-4.22%	+17.96%
JATT JATT Acquisition	+8.16%	+1.27%	+22.31%	+32.50%	-51.67%
MGNX MacroGenics	-2.41%	+0.62%	+8.72%	+2.53%	-51.50%
ZURA Zura Bio	+8.18%	+16.22%	+32.31%	+54.95%	-47.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COYA Coya Therapeutics	1.6648 of 5 stars	3.5	2.0	0.0	0.0	1.7	0.8	0.0
JATT JATT Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	4.3346 of 5 stars	3.3	3.0	0.0	4.4	2.9	2.5	0.6
ZURA Zura Bio	3.8604 of 5 stars	3.6	5.0	0.0	0.0	4.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COYA Coya Therapeutics	3.00	Buy	$16.50	168.29% Upside
JATT JATT Acquisition	0.00	N/A	N/A	N/A
MGNX MacroGenics	2.57	Moderate Buy	$3.60	127.85% Upside
ZURA Zura Bio	3.13	Buy	$14.17	753.41% Upside

Current Analyst Ratings Breakdown

Latest JATT, COYA, ZURA, and MGNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	MGNX MacroGenics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $5.00
8/15/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $16.00
8/15/2025	ZURA Zura Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/13/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
8/13/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
7/24/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
7/9/2025	COYA Coya Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$16.00
7/1/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
6/9/2025	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
5/20/2025	MGNX MacroGenics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COYA Coya Therapeutics	$3.55M	28.98	N/A	N/A	$1.69 per share	3.64
JATT JATT Acquisition	N/A	N/A	$0.06 per share	27.08	($0.53) per share	N/A
MGNX MacroGenics	$149.96M	0.66	N/A	N/A	$1.85 per share	0.85
ZURA Zura Bio	N/A	N/A	N/A	N/A	$2.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COYA Coya Therapeutics	-$14.88M	-$1.24	N/A	N/A	N/A	N/A	-61.05%	-53.61%	N/A
JATT JATT Acquisition	$6.85M	N/A	0.00	∞	N/A	N/A	-49.58%	2.84%	N/A
MGNX MacroGenics	-$66.97M	-$0.89	N/A	N/A	N/A	-36.23%	-59.84%	-23.45%	8/19/2025 (Estimated)
ZURA Zura Bio	-$45.39M	-$0.70	N/A	N/A	N/A	N/A	-42.84%	-35.22%	N/A

Latest JATT, COYA, ZURA, and MGNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	MGNX MacroGenics	-$0.59	-$0.57	+$0.02	-$0.57	$28.06 million	$22.24 million
8/14/2025	Q2 2025	ZURA Zura Bio	-$0.19	-$0.17	+$0.02	-$0.17	N/A	N/A
8/12/2025	Q2 2025	COYA Coya Therapeutics	-$0.22	-$0.36	-$0.14	-$0.36	$0.78 million	$0.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
JATT JATT Acquisition	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COYA Coya Therapeutics	N/A	7.43	8.84
JATT JATT Acquisition	N/A	0.15	0.15
MGNX MacroGenics	N/A	3.28	3.11
ZURA Zura Bio	N/A	8.14	8.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COYA Coya Therapeutics	39.75%
JATT JATT Acquisition	47.97%
MGNX MacroGenics	96.89%
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
COYA Coya Therapeutics	12.00%
JATT JATT Acquisition	20.00%
MGNX MacroGenics	13.00%
ZURA Zura Bio	14.23%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COYA Coya Therapeutics	6	16.73 million	14.72 million	Not Optionable
JATT JATT Acquisition	3	17.25 million	13.80 million	Not Optionable
MGNX MacroGenics	430	63.09 million	54.89 million	Optionable
ZURA Zura Bio	3	68.38 million	58.65 million	Optionable

JATT, COYA, ZURA, and MGNX Headlines

Recent News About These Companies

Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

August 14 at 8:15 AM | businesswire.com

Zura Bio (ZURA) to Release Quarterly Earnings on Tuesday

August 11, 2025 | americanbankingnews.com

Zura Bio Limited (NASDAQ:ZURA) Receives Average Recommendation of "Buy" from Brokerages

August 7, 2025 | marketbeat.com

Zura Bio (ZURA) Projected to Post Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Shares Up 7.5% - What's Next?

August 6, 2025 | marketbeat.com

Robert Lisicki on Living Up to Zura Bio’s Heroic Namesake

July 31, 2025 | pharmexec.comP

3 Penny Stocks With Market Caps Over $70M Worth Watching

July 18, 2025 | finance.yahoo.com

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 18, 2025 | finance.yahoo.com

Zura Bio Announces Chief Financial Officer Transition

July 1, 2025 | businesswire.com

Zura Bio shareholders approve board nominees and auditor

May 24, 2025 | investing.com

Zura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativa

May 21, 2025 | msn.com

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

May 20, 2025 | businesswire.com

Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 9, 2025 | standard-journal.comS

After losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain

April 24, 2025 | finance.yahoo.com

Zura Bio price target lowered to $3 from $5 at H.C. Wainwright

April 4, 2025 | markets.businessinsider.com

Zura Bio (ZURA) Gets a Buy from Guggenheim

March 31, 2025 | markets.businessinsider.com

Hopeful Week For Insiders Who Bought US$1.01m Of Zura Bio Stock

March 26, 2025 | finance.yahoo.com

Zura Bio Limited: 2024 Financial Results and Strategic Progress

March 25, 2025 | tipranks.com

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

March 25, 2025 | businesswire.com

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

February 24, 2025 | businesswire.com

ZURA stock touches 52-week low at $1.44 amid market shifts

February 11, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JATT, COYA, ZURA, and MGNX Company Descriptions

Coya Therapeutics NASDAQ:COYA

$6.15 +0.46 (+8.08%)

Closing price 04:00 PM Eastern

Extended Trading

$6.08 -0.08 (-1.22%)

As of 04:11 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

JATT Acquisition NYSE:JATT

$1.72 +0.13 (+8.18%)

As of 08/14/2025

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.

MacroGenics NASDAQ:MGNX

$1.58 -0.04 (-2.47%)

Closing price 04:00 PM Eastern

Extended Trading

$1.58 -0.01 (-0.32%)

As of 04:10 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Zura Bio NASDAQ:ZURA

$1.66 -0.06 (-3.49%)

Closing price 04:00 PM Eastern

Extended Trading

$1.65 -0.01 (-0.60%)

As of 04:18 PM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time